Pharmaceuticals

HYBIO

HYBIO released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 283.23 M, actual EPS CNY -0.0354

HYBIO released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 299.15 M, actual EPS CNY 0.14

HYBIO released FY2025 Annual Earnings on April 28 After-Market (BJT), Actual Revenue: CNY 966.35M, Actual EPS: CNY 0.04

HYBIO FY2025 Annual Earnings Release on April 29, 2026 After-Market (BJT)

HYBIO to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

HYBIO released FY2025 9 Months Earnings on October 29 During-Market BJT, actual revenue CNY 683.12 M, actual EPS CNY 0.0735

HYBIO released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 133.68 M, actual EPS CNY -0.0864

HYBIO FY2025 Q3 Earnings Release on October 30 During-Market BJT

HYBIO released FY2025 Q2 earnings on August 22 During-Market BJT, actual revenue CNY 239.47 M, actual EPS CNY 0.08

HYBIO released FY2025 Semi-Annual Earnings on August 22 During-Market BJT, actual revenue CNY 549.44 M, actual EPS CNY 0.16

HYBIO FY2025 Semi-Annual Earning Release on August 22, 2025 (BJT)

Hyundai Pharmaceutical and KuCoin Partner to Explore Tokenization Pilot Project for Innovation Drug R&D Future Revenue Rights

Huayu Pharmaceutical Experiences Large Block Trading

Huan Yu Pharmaceutical Announces Significant Profit Growth for H1 2025

Wyeth Pharmaceuticals Reports Significant Q2 Earnings Increase

HyuMed and Carbon Cloud Peptide Sign Cooperation Agreement

Huayu Pharmaceutical Expected to Turn Profitable in 1H2025

Hanyu Wuhan's Acetate Degarelix Active Pharmaceutical Ingredient Receives Marketing Approval

Huan Yu Pharmaceutical HY3003 Project Roadshow Introduces Progress

HuanYu Pharmaceutical's Semaglutide Injection Phase III Clinical Trial in Follow-up Stage

300199

HYBIO plans to issue A-shares to no more than 35 specific investors, raising no more than 968 million yuan. The issuance price will be 80% of the average price of the 20 trading days prior to the pricing benchmark date. The raised funds will be used for the expansion and construction of peptide drug production lines, green intelligent upgrades, research laboratory upgrades, and to supplement working capital

Zhitong

HYBIO plans to raise no more than 968 million yuan through a private placement for multiple projects and to supplement working capital

HYBIO announced that the company held a board of directors and supervisory board meeting on September 25, 2025, to review and approve the proposal for the issuance of A-shares to specific targets for the year 2025. The relevant preliminary plan and announcement have been disclosed on the Giant Tide Information Network. The related matters of this stock issuance still require approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission

HYBIO: Plans to issue A-share stocks

603998

600232

The industrial hemp sector has undergone significant adjustments, GETM has hit the limit down, and HYBIO, Fangsheng Pharmaceutical, and Bohai Chemical have followed suit

Fangsheng Pharmaceutical

GETM

The industrial hemp sector has undergone significant adjustments, and GETM has hit the daily limit down

According to the Zhitong Finance APP, HYBIO released its semi-annual report for 2025, showing an operating income of 549 million yuan, a year-on-year increase of 114.86%. The net profit attributable to shareholders of the listed company was 145 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 123 million yuan. The basic earnings per share were 0.16 yuan

HYBIO released its performance for the first half of the year, turning a loss into a profit of 145 million yuan

HYBIO announced that the company has received the "Drug Registration Certificate" issued by the Drug Administration of the Ministry of Health of Vietnam, granting market approval for its product "Atosiban Acetate Injection" in Vietnam. This medication is suitable for pregnant women with indications of preterm labor, used to delay imminent preterm birth, with good clinical efficacy and minimal side effects. The market approval of this medication will further enrich the company's overseas product pipeline and expand its overseas market. The company will actively promote the sales of this medication in overseas markets to enhance its international brand influence and overall competitiveness

HYBIO: Acetate Atosiban Injection has obtained marketing authorization in Vietnam

HYBIO has signed a series of commercialization agreements with Zhejiang Sanofi-Mandi Pharmaceutical, including the "Semaglutide Injection Entrusted Production and Supply Agreement" and the "Quality Agreement." According to the agreements, the expected annual sales peak is 30 million units, and the supply price will be quoted in phases based on sales forecasts. The drug will be co-produced as a Class 2 modified new drug in China and the United States

HYBIO: Signed a series of commercialization agreements with Sanofi, with the weight loss drug expected to reach a peak annual sales of 30 million units

HYBIO rose over 10%, Sun Pharmaceutical, Kingmed Diagnostics, and Lepu Medical rose over 5%, while Baihua Pharmaceutical, Changshan Pharmaceutical, Shengnuo Biotech, Haofan Biotech, and Deyuan Pharmaceutical also saw gains. On the news front, the U.S. FDA has expedited the approval of the supplemental new drug application for its blockbuster therapy Wegovy, intended for the treatment of adult patients with metabolic dysfunction-associated fatty liver disease with moderate to severe liver fibrosis. As a result, Novo Nordisk's U.S. stock rose over 6% in after-hours trading

Weight loss drug concept stocks fluctuate and rise, HYBIO increases by over 10%

688336

688098

300049

688621

688091

In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

Sunshine Guojian Pharmaceutical

Shen Lian Biomedical

Furui Co.,Ltd.

Sun-Novo

SHANGHAI YIZHONG

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

002275

300436

001367

002728

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit

Guilin Sanjin

Cosunter

Haisen Pharm

TY PHAR.

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

688110

China's stock market saw a rebound on Monday, with the Shanghai Composite rising 0.66% to 3,583 and the Shenzhen Component increasing by 0.46% to 11,042. This uptick was driven by investors buying the dip following last week's decline. However, concerns linger as the recent Politburo meeting did not introduce significant stimulus measures to combat slowing growth. Traders are also monitoring the US-China tariff situation, with the current truce set to expire on August 12. Notable gainers included Contemporary Amperex (1.3%), Dosilicon Co (20%), and Hybio Pharmaceuticals (20%).

Trading Economics

Dosilicon

China Stocks Rebound on Dip Buying

HYBIO(300199.SZ)